Company intelligence / Profile preview

Goldenrod Therapeutics

Houston, Texas, United Statesgoldenrodtherapeutics.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Goldenrod is developing 11h, a small molecule that has shown evidence in various disease states and is preparing for IND-enabling studies. Their compounds are designed to be orally bioavailable and brain-penetrant while avoiding adverse events like nausea associated with current inhibitors.

Therapeutic areas: PsychiatryImmunologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

sibirin

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Goldenrod Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Goldenrod Therapeutics.

Explore the full profile